SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 232 filers reported holding SAGE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,319,000 | +1504.8% | 550,000 | +3566.7% | 0.04% | +800.0% |
Q2 2023 | $705,300 | -86.9% | 15,000 | -88.3% | 0.01% | -79.2% |
Q1 2023 | $5,398,406 | -51.2% | 128,656 | -55.6% | 0.02% | -78.8% |
Q4 2022 | $11,060,600 | -4.3% | 290,000 | -1.7% | 0.11% | +10.8% |
Q3 2022 | $11,552,000 | +21.2% | 295,000 | 0.0% | 0.10% | +41.7% |
Q2 2022 | $9,529,000 | +539.5% | 295,000 | +555.6% | 0.07% | +260.0% |
Q1 2022 | $1,490,000 | -29.9% | 45,000 | -10.0% | 0.02% | -9.1% |
Q4 2021 | $2,127,000 | +92.0% | 50,000 | +100.0% | 0.02% | +46.7% |
Q3 2021 | $1,108,000 | -82.2% | 25,000 | -83.3% | 0.02% | -86.2% |
Q2 2020 | $6,237,000 | +141.3% | 150,000 | +66.7% | 0.11% | +67.7% |
Q1 2020 | $2,585,000 | +84.2% | 90,000 | +800.0% | 0.06% | +66.7% |
Q3 2019 | $1,403,000 | -23.4% | 10,000 | 0.0% | 0.04% | -7.1% |
Q2 2019 | $1,831,000 | -42.4% | 10,000 | -50.0% | 0.04% | +2.4% |
Q1 2019 | $3,181,000 | +66.0% | 20,000 | 0.0% | 0.04% | +57.7% |
Q4 2018 | $1,916,000 | +207.5% | 20,000 | +100.0% | 0.03% | +73.3% |
Q3 2017 | $623,000 | – | 10,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Integral Health Asset Management, LLC | 311,000 | $10,294,000 | 2.68% |
Palo Alto Investors LP | 851,719 | $28,192,000 | 2.18% |
Boxer Capital, LLC | 1,094,000 | $36,211,000 | 1.86% |
DAFNA Capital Management LLC | 180,306 | $5,968,000 | 1.56% |
Deep Track Capital, LP | 675,000 | $22,343,000 | 1.43% |
Bellevue Group AG | 3,052,404 | $101,034,000 | 1.17% |
Ikarian Capital, LLC | 250,000 | $8,275,000 | 1.09% |
Ikarian Capital, LLC | 249,907 | $8,272,000 | 1.09% |
Artal Group S.A. | 750,000 | $24,825,000 | 1.04% |
SECTOR GAMMA AS | 118,476 | $3,922,000 | 0.85% |